Drug User Internet and Mobile Tech Use

This study has been completed.
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Silvia Cunto-Amesty, Columbia University
ClinicalTrials.gov Identifier:
NCT01871298
First received: June 4, 2013
Last updated: November 25, 2015
Last verified: November 2015
  Purpose
The purpose of this exploratory study is to examine factors associated with frequency and type of internet and mobile technology use among illegal drug users, specifically use of internet and text-messaging to obtain health care information and engage in health care utilization, specifically human immunodeficiency virus (HIV) prevention and treatment services. We will target high drug activity neighborhoods in New York City and enroll participants recruited through targeted street outreach. All participants (n=336) will undergo an audio computer-assisted self-interview (ACASI) that will assess sociodemographics, health care access and utilization, sex/drug use behavior, health status, and characteristics of general and health-related internet/mobile technology use including factors that promote or hinder use. Participants identified as using the internet ≥1/month (n=151) will return for a 4-week ACASI to report on use of the pilot website (which will largely display information currently available in the community in print/ pamphlet/ video form).

Condition Intervention
Drug Abuse Illicit
Other: Pilot Website Evaluation Component

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Exploratory Study of Drug User Health-related Internet and Mobile Technology Use

Further study details as provided by Columbia University:

Primary Outcome Measures:
  • Percent of participants who use the pilot website [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Percent of participants who use the internet [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Percent of participants who use the internet at least once a month [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Percent of participants who use the internet for health-related purposes [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Percent of participants who are willing to use internet or mobile technology for health-related purposes [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Percent of participants who sign up for receipt of automatic text message updates on relevant health information [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Enrollment: 212
Study Start Date: December 2014
Study Completion Date: November 2015
Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Website access
While this pilot intervention is not a randomized trial, study participants who report internet use at least once a month will told of a Pilot Website Evaluation Component that they will be able to access for a 4-week study period. This website will contain a educational information tailored to the health needs of drug users. Web content will be similar to materials and public health messages released by the NYC Department of Health and therefore, harm is not likely to arise from viewing such content.
Other: Pilot Website Evaluation Component
The pilot health website will contain educational health information such as: health-related videos, searchable map of HIV prevention and other needed health and social services, and the option to register for automatic text message updates on relevant health information.
No Intervention: No website access
Participants who report internet use less than once a month will not receive access to the Pilot Website Evaluation Component.

Detailed Description:
At the enrollment visit participants deemed eligible after screening will be consented, and given a 30 minute baseline ACASI survey. At the end of the baseline visit, those participants who reported internet use at least 1x/month (in the past month) will be offered participation in the Pilot Website Evaluation Component. For this component, participants will be instructed on how to use an educational website with health resources. Their use of the website will be tracked. They will be given an appointment to return in 4-weeks for a follow up survey at the pharmacy and a 2-week locator call.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • any lifetime illegal drug use
  • age > 18

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01871298

Locations
United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
Sponsors and Collaborators
Columbia University
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Silvia Cunto-Amnesty, MD Assistant Professor of Medicine and Population and Family Health, Dept of Medicine Family Med
  More Information

Responsible Party: Silvia Cunto-Amesty, Assistant Professor, Columbia University
ClinicalTrials.gov Identifier: NCT01871298     History of Changes
Other Study ID Numbers: AAAL6402  1R21DA034841-01A1 
Study First Received: June 4, 2013
Last Updated: November 25, 2015
Health Authority: United States: Federal Government

Keywords provided by Columbia University:
internet and mobile technology use
history of drug use
injection drug user (IDU) syringe customers

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders

ClinicalTrials.gov processed this record on August 24, 2016